Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
Fox
Robert I
RI
Allergy and Rheumatology Clinic, Scripps Memorial Hospital and Research Foundation, La Jolla, California, USA.
D006801:Humans; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D011812:Quinuclidines / Q000627:therapeutic use*; D043643:Receptor, Muscarinic M1; D043587:Receptor, Muscarinic M3; D011976:Receptors, Muscarinic / Q000187:drug effects*; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D013876:Thiophenes
D018721:Muscarinic Agonists; D011812:Quinuclidines; D043643:Receptor, Muscarinic M1; D043587:Receptor, Muscarinic M3; D011976:Receptors, Muscarinic; D013876:Thiophenes; C059240:cevimeline